LU505117B1 - A pan-KRAS inhibitor compound - Google Patents

A pan-KRAS inhibitor compound Download PDF

Info

Publication number
LU505117B1
LU505117B1 LU505117A LU505117A LU505117B1 LU 505117 B1 LU505117 B1 LU 505117B1 LU 505117 A LU505117 A LU 505117A LU 505117 A LU505117 A LU 505117A LU 505117 B1 LU505117 B1 LU 505117B1
Authority
LU
Luxembourg
Prior art keywords
int
mmol
compound
reaction
esi
Prior art date
Application number
LU505117A
Other languages
English (en)
Inventor
Yufeng Chen
Feifan Li
Meng Lv
Wanli Cheng
Kaixuan Chen
Canfeng Liu
Han Yang
Shuaishuai Liu
Nanhai He
Original Assignee
Adlai Nortye Biopharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adlai Nortye Biopharma Co Ltd filed Critical Adlai Nortye Biopharma Co Ltd
Priority to LU505117A priority Critical patent/LU505117B1/en
Application granted granted Critical
Publication of LU505117B1 publication Critical patent/LU505117B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (2)

  1. on fo) © © 4e, ee, ele GO LU505117 / o "ox, Le de TH fon Os SN 0 ° N 76H / yA on / o oA A I Fy oN © N J, N ® 0 ñ © / NTN N SS = > Nes Pa n=l," ” = NS A > NA = N = N N Ny ÿ 4 — J N — A + / oN où Jd / A) - (a \ ON \ Os X oO o GA 0 ©) A $ N ©) i 5 N 9 Oy neo Og NG / NON O on, À à Mel À EN i o N J NN / Neo / o Mol doe 3 N= LUN a n=l " (Le ‘yg N © ° H X N SS 5 N= 2 N= ®\_0 N = S NA NA N = N AS N N (4 7 rN N J J _ ) — f — Ÿ Ÿ / J oj J WN dN ON Oy GA IN d Or GA 0 0. Gr 0 0 © 0 Toy A TN 1 3 N 1 hi wre { / NT NS 0 ol, A 0 ex, À Ho N © NN oS NN / a / © ue, 5 Na 5 wd #10 0 H 0 H > > © N= ANN a, N= © <>; = N: 5 N LS > Ss } 4 "Ng NS NA > N — N N Va Ÿ — J — J oh oN ( / dN / / \ oN o la de GA GA | © N Ou NO es d Ho X bi N 1 oy N° e vs esp / N oO (S) o Hu À SON o 9 N / N / NN o fy or © N qd, H 0 H / N N = NA, Sy N= (Le Og F o NA À N= > N = S X v / rN N > > N N ON ÿ / J J N — AN — / oq N Jd 7 —_ À — \ _ oN oo A oy Ge 95 Os lod oO ©. 6 oO ex N a 9 SONT a OSSI SE / 9 hd, / oT Ay 5 / 3 Fo LE, 3 Mol AC 0 ñ N 3 NA + 9 Nn Og nA * Og EO 9 dy 6 N = N Ss Ss N= A MN = MN 0 = NA | 7 N N N = + + N I — 7 7 yo oN \— \ ON oO N A ox, Ge °, mn Os es o 4 o. fo o o. fa o Hu Jete q N s) 1 3 N 9 + N D; J N / NON / 9 9 n° Los / © Fy 5 N 9, HOLA 9 H 9 0 N N ~ SL, N=" (8) 5] N Ls N AS s Ne an MN Mg > My = o” N — N N 7 J — J J — — MH 4 oN oN oN ON y \ \ ooo où © N Os NL50 HO AS 6) A Fe 1 = 0H TON 4 A Os à 7 Ox ® NO / NN o "Ah om 6 "A J | IN L = d MONT / NOONTSH / NON Fel N 5 = Q H o H ©) / NON © 5 Na © N J OC N = N Ss s 2 N= NÉ X N > 5 4 7 rN N > 5 N N NZ Ÿ y A 4 J N IN — 4 ÿ — IN IN IN — Àf i \ oN dN i ole) 0 Os GA 0 ©} ©} J H © 1 TH q Oy Na ose J NONE / oO 128 , o Mok J @ JH ie 3 YA» en Og Ea © de nd A ty d, OR © NA 7 > NA => N VS Me Ÿ 4 } 4 A NS 7 > N J J J N IN 4 + Ÿ ÿ ÿ — dN / 7 ON aN i ole do ole No © © 8) 5 38 OO NO OS 3 H (5), A A H 5) 1 1 N i 5 hy N ’ fi id y Te 0 (5) © ô ok, À Ho À J J, N 5 J SLIN N 5 J ON NT / © SN > #55 PE 9 QT 5 @ nA Og Lo Ng = N SS N Ds N Na N AN ¢ UNNA yo — N N Va fo — J J A — — 7 7 oN oN od nN 9 i \ N
    BL-5758 GO 6 6 ©) LU505117 5) Ss) 5) oy NN °° Os WN © oy NN à Op ZN °, o "eu À © o Hoel Je / o FM © o "Tu À © J NA 9 n°6 0 N J NRE 5) N= 5) N= > 5) N= > 5) N= N 2/8 = = = NA NA 4 NA 7 A N N N N J = , À 1 À — NS Nu N N Lg > /
    os. yh Pa os y °9 Og y” °e ; 1 te o (9 oO (3) go) fo) (3) (9 70 J, VE d NE d NE “a nl S) N= > Ss) N=" > S) N= > N Ss = = = Lu A NS 7 PN 4 MN Da N N N J / Jo Jo ya 7 & ® & © N N N N / / GA © 6.1 oA Op SN 9 Os EN oy oy SN °° Oy y" 95 o Hu Je à Hel Jeg o Hoel Je , o ON J 6 À n°6 J SE 5 HG S) N= S) N= S) N= 5) N= s A AN A NA 9 > N > N a o / / . © ® N N— cy N N
    \
    0. lo ° 0, fk Pa oa ° os. oH °0 oO & bs) oO ©) bs) oO (3) (5) oO (3) (5) J, ONE d, WE dd. Ty Ed Thy Vo NA Ms NN AR N _ N N / / J = Jo — A (9 ® Hn NP N Un oy GA °° Oy GA °e Oy GA °° Oy GA 90 H H H H ° oh Js 0 ok Js ° SA, À o À, Js
    4. de VE d, ONE dd. aL d. Ba SS = 8 Ss NS 9 A Mg NA N N — DB mn / / / = og N Sn CN oN Oy A 9 Os GA 99 Os GA °o Oxy GA 99 , o Hel Je 1 Hol Je , o Hoel Je , o "ek Je d. a 4. ve J. a 4. RA NS 9 Mg NA 9 NA N N _ N 4 J —A / / as 0/7 N SON N N: HN Ny Cr OH 0 \ 119 ogo, ogo, ols Ge LU505117 H CN © SUNT a oO aly Ms o "ell J H 5 / nH y AD A 0 oN, À a Hou “2 A © Os N= H © Jd NRE J N pe > 5 N= ( = N = N ee LS 5 (> 4 CN Pv ny > JN { N N / ÿ # \ y N u a — Ny X y NN Ney X Os X o 6) X i N o Os. EN Os ©. oy feds 1 FFLier SDS TCs 0 À, Ao 9 H S / © Pa / © Ta de A ve N 2 = “a IE ve Og, EO ve = 5 5 Ng ~~ @ 4 oO NA 7 @ NA > N A ç N N / Q ( ÿ N ÿ N ® Q SS cl N NS NH,
    ox. oy o Shen Q a a sly À, Oso NO Osi NO © d N te Z TN 1 SUN 9 Oy NMC © H 0 oN Jo o ol À H . = d Ne / N C6 A / a © ws NA 7 7 = N= “ea nA © A wel " © N = SS 5 > NS NA NS = 7 5 N N / Ÿ : # — \ ÿ — CO 9 CN IN © 7 — \ AN = 9 OS NO rE NO OO M0 / A “© y Te J Ho 5 © / 2 He 5 © J He 3 (DS a LVO de NUR de Na dr NZ > N= = n= N = 5 SS 5 CS Mg > Nv NS 4 > - A Bm _ 5 > . / FN ~ 4 SN ÿ IN A \ o N Og N Om N \ od Ho Os, © 9, Oy © 06 Os 6) o o. 6) o COTY, , 2° A o YC, WLS 5) / (5) ad, wd # Vo Os N= N de Na N A dq, N No N > = N = 5 5 Mg ad n=) = Lu ~ N N J J _— } A Ÿ + À / J + ON 9 ay © ay N Cw “Ron 5 PR) is) Ho OH on Os © 9, Ox. 6) o Os © o 0. © o oo ee AL PEE TL d N © NRE / No © © n= de vd # © od WL Hh ve J N NRA N os 5 > A a Da © 4 5 7 7 — 5 N N — J ya J ore a or Ow d d \ \
    oc lao oc lado on le he oo lao LUS05117 1 He 3 (8) 3 He 3 © 3 How 3 © 3 He 3 © o N RE o N Ci o N Ci o N Ci 3 N= a N= a N= a N= YN 7 > NE 7 > "A > MN 7 > _— _— _— _—
    HO.45) Ÿ HOW) Ÿ EF. 7 Fa® 7 DO Tn © +, or bod °e DR O5 on °e DR 9a H i H | Hol À ° A, Js à Hl J. y Ô SA, Ais y o [A A x A iv] 4, N N qd, N Ne J, ea J Ss = Ss 8 NA > Nf 7 as Mg N N N N Jo / / J — PR 99 ou ih ° 0 ou oh 05 or lh °°
    N . ; ° sh is o Hk Jl H | H (5 4 hte do LWA Cw 4 = = a = . = x = 5 Hy . = 4 PN a Ne N N N ZA 4 a vo ° N > Og LP (D Dr {Ln Oy GA Oo Ope (A © Oy GA 99 Os (A 9 / © A te @ qd Hol de , o "el Je , o "eg el @ Og Ea d N IE 0 of To d H ¥ N Ny © N= 2 n= Q N= LÀ N = N => N — N A yg a J Bi > > N 7 I A any ÿ I 4 ! gn $ N d N GS \ \ \ 5 Oy GA a Oy GA © Oy GA 99 Oxy GA o H ON a 0 hy Hu o Hel J. o Tel J. TH oO Adee X Ver 4 Ver LA Re 2 N= 9 N= Q N= °g Ea N VS N Ny N = SS Di AS NS NEA 5 5 N 7 A A Jo N N N \ al N o <q ol J N 0 ©) nn H | H I o ol Mg / Tha o ok, Ag o EX, hs J A 6 Ce 14 A VO of N°75 J on ec 3 NA, N Ts 3 N= 3 N= Ç = NA > ai NA NA à N N N N AN J ya = J N Ÿ \ N Y . Ÿ N N N = TS > oS \_/ N ° 121
    BL-5758 LU505117 Ansprüche
    1. Verbindung mit einer Struktur der Formel (I) oder ein pharmazeutisch annehmbares Salz, Isotopenderivat oder Stereoisomer davon: NT O o O (R) yo N= Rs" Ra s N J Re / \ Ÿ — N J Re’ Ry Ra m R7 R7' (D wobei Rı steht für C1-Ce-Alkyl, vorzugsweise C1-C3-Alkyl; o— o— Ra steht für = , Vorzugsweise À ; Rs steht fur -O(C1-C6)-Alkyl, -O (Co-Cs-Alkylen) (C3-Cs) Zykloalkyl, -O (Co-Ce-Alkylen) (3-8 gliedriges) Heterocycloalkyl, -O (Cz-C6-Alkylen )RL oder Wasserstoff, -Cy1-(R4) in der Formel (I) ist ausgewählt aus den folgenden: 1
    BL-5758 on > Fo ; . bn me LU505117 (9) {0 +. x “né NA + Ve 7 V6 Re “RA F NTP " (> “rh WAN SA Ey © LUN _o who EN Ss) N° N (S) N RS #8 . N A N. 7 RR NC 70 Ne * © NLP “Rg ©? ©) O s) N (s) (Ss) (s) (R) S N N N — re LM / (9 Ro *.(5) - “er “As NA ue 76 oH in OH “6 © / ~, HO | oO o cor + d Soo. * AN ; * + (9/R N 3 QG .. 6 0 NG a A 9 N A O À
    +. NT te WK we do x, = | 208 # IJ (S) ) un Lo wobei, * steht für die Stelle, an der -Cy1-(R4)p mit der Verknüpfungsstelle in Formel (I) verbunden ist; Rs steht fiir-Cy2-(Rs)q oder-NRoRo', wobei, -Cy2-(R5)q in der Formel (I) ausgewählt ist aus den folgenden: 2
    BL-5758 . ; , LU505117 . * ÿ * ®) = ei © (R) (Ss) = of of ot CN Ë Ci- N (7 / / \ cS X as D d X 37 N- LH a N-* DR 7 a \ = rn Yen ja or a A AS N Cop (s) (A) Cx NTT AAMT 4 4 Co Cg NT _, / NX, Ses _ /\ /\ IN {Nm 0 Re = * Sp Op N° Le Aer “Un OH Q HO Ho OH nd _ HO.(s) HOR) 0 N IN De * Re ee “Un AD IN x OST = = CH QC = TS Ne ANT M MN SM A SG 84 N-N NH, N N wobei, * steht für die Stelle, an der -Cyz-(Rs)g mit der Verknüpfungsstelle in Formel (I) verbunden ist;
    Ro and Ro jeweils stehen unabhängig voneinander für C1-C6-Alkyl , das gegebenenfalls durch q Rs substituiert sein kann;
    Rs steht für Wasserstoff, Halogen, C1-Ce-Alkyl, -(Co-Cs-Alkylen) ORa, -(Co-C6- Alkylen) NRaRa'; oder Rs an den beiden C-Atomen von Cyz zusammen mit den damit verbundenen C-Atomen und den Atomen zwischen den beiden C-Atomen einen 3-8- gliedrigen Ring bilden kann, und der 3-8-gliedrige Ring gegebenenfalls 0, 1, 2 oder 3 Heteroatome, ausgewählt aus N, O oder S, enthalten kann; oder zwei Rs an demselben C-Atom von Cy: sind und das damit verbundene C-Atom einen 3-8-gliedrigen Ring bilden kann, und der 3-8-gliedrige Ring gegebenenfalls 0, 1, 2 oder 3 Heteroatome, ausgewählt aus N, O oder S, enthalten kann;
    3
    BL-5758 Rs und Re stehen jeweils unabhängig voneinander fiir Wasserstoff, Halogen, C1- LU505117 Cs-Alkyl, C3-Cs-Cycloalkyl oder -(Co-Ce-Alkylen)CN; R7 und R7 stehen jeweils unabhängig voneinander für Wasserstoff, C1-Cs-Alkyl; oder R7, R7 bilden einen 3- bis 8-gliedrigen Ring mit dem daran gebundenen C-Atom, und der Ring kann gegebenenfalls 0, 1, 2 oder 3 Heteroatome, ausgewählt aus N, O, S, enthalten; besonders bevorzugt steht R für Wasserstoff, wobei p und q stehen unabhängig voneinander für 0, 1 oder 2; m steht für 0, 1, 2 or 3; Ra und Ra' stehen unabhängig voneinander für Wasserstoff, C1-C6-Alkyl und Cs- Cs-Cycloalkyl; wobei, wenn Ra und Ra' mit demselben N-Atom verbunden sind, Ra und Ra' mit dem gemeinsamen N-Atom verbunden sein können, um einen 4-8- gliedrigen Ring zu bilden, der gegebenenfalls 0, 1, 2 oder 3 Heteroatome, ausgewählt aus N, O oder S, enthalten kann; jedes der Alkyl-, Zykloalkyl-, Heterocycloalkyl- und Alkylengruppen kann unabhängig voneinander durch 0, 1, 2, 3, 4, 5 oder 6 Halogenatome substituiert sein.
    2. Verbindung mit der folgenden Struktur: Ce TVR DR aS 0220 rr avan avan SA rrr SA aan 4
    Ou © oO On ex oO Os CA oO 0 Go oO U505 TON a SON 9 TN 9 N SOON 9 _ / © 9 120 / 9 TONNE on / © eg / 0" nw a 0 H © o H ® J H © 9 N ® Q N= 9 = 3, N= 9 N= 5 5 N = N = s NM NA 4 > AN N = J 5 _ N / / / vo I I an I ag NN aN oN oN GA © © © os, yn IN Os un 0, Og y" IN Og y" CIR x 0 ©) od J 0 & Ad J 0 ©) y" 980 / 0 ©) y" 06 5 nA LUN. g n=l Lo 3 NA, Og N= N 0 NA > NS > NS 7 = AR = — A 0 N / ÿ / J I I I I oN ON CN ON / \ \ \ 6 / ©) 6) N S) S) (5) Oa „N oO Os y" 0, 9% Oy y" IN os, y" 2 5% 0 \ ©) / 0 © Ve J 0 ©) ih d 0 © y 0 J 0 172 Og NA " ©, N= Ao 9 N= N N © NA, © 5 5 5 N = N S N = NS 4 > SA NS NS N N N N — D — ro + / / / oN oN ON ON / \ \ \
    9. es 9 0. © 0 0. fn 0 N 61 SONT 0 SON 0 SON 9 > ur No ; à He N , J Hg N , à Hg . A à Hg SE N ( / N Ca = H Od N= H 0x N= H L_o Og Na H 0 5 5 5 N = N N N = 5 MN NA CS ARN = J J N J J ÿ yo oN aN oN JN dN GA © GA © Oy NN 09 Oy i 90 Oy y" 09 N oy i 0 à (5), 6) , Lu Ne ON. de Ne 0e N= 0 de wl 5 5 5 s s A > NS > NA > NI > _ A A N / A / yo Van I I I oN oN oN ON \ \ \ NS bla, N © | © 0 Oxy goN_0 à Op y" 0, 0 Oy y" IN SR s , o Hg Arado , 0 A, Ly , 0 © me , ° oh A X “ 0 H Se n=l Hf Oa N= A UN RT N= Too 2 N= 5 N N 0 A > Mg > AN > RZ N N N N — J — Ÿ — Ÿ ÿ Ÿ I IN IN Jd N A \ \ \ Q Q Q Q os y” °0 om os NO HO ON 5, = ONO _ 0 oh JF 6 Hoel JL em o Mol Je J So Falk LN J N NT / NOONTTR J N oN / N NT & N= Og Ne a N= Og nH 5 s 5 N = N = N N 5 NS A rN Nv — N N N / Jo Ÿ yo oN oN oN SN oN \_Y \ \ \ © GA © a] Oy y" 0, Os u IN | Oxy y” à os; y” 20 / © 9 Hd / © On 2 / © 9 N N° 9 / 0 wd ho 5 Og N ON Og n=l © Og N= ®" Og N= qu æ Ss <5 N 5 s NA NA 4 NS NA = — — — J 4 A A A oN | oN ( CN ‘ CN g / / \ \ © © © en ON os, NO à Os NO 5% ow o "aN leg o Hel À @ o Hel | 7 0 a) À, x / SN / OR NTN 0 / SON NY / SN Q oH © 9 oH 9 oH Og oH Q N= ® 3) N= © 3) NAD NAD N Ts] N IN N 5 N 5 7 % 2 Ny rN Ny N N N N — — / —A — / ÿ J oN ON oN oN / / \ \
    BL-5758 GO GC N ©) LU505117 0 9 NO Oo, NO Ose SN oy Oo, GN o + H (3) io / 4 H & J © / 1 Ho u Lo / d Hos) A © J, Ne N To a, wel A VE a, nd # Vo 9 nd # To N 0 NA 7 NA 7 NX 7 N D N N = / A 0 NS N° (@æ N A + Ce / o lol o ol lon o el o TN 9 1 H ) Jo d H 5) 3 © + H ) Jo J ° / ve; J N To J N To J N Go S N= Ss) N= S) N= S) N= N 8 8 SS SS X ZZ A NA NA 4 \ N N N N — / / J / — ÿ — y on (® o=( Ca Cy N N \ \ Oo, on oO oon oO Os où oO Ou GA o ° d He Î © 1 He fe , d He A © , A How Ae d. N N Ve J, Ne N © J, y À ve 0, a Vo =F SS SA N SS NA 7 AR NA 4 rN HAM N N N N — J J — J — / ©, ey A ve oy GA 9 Os GA 99 oy lo ° 0 Oy GA 9 o Hol Je o MeN Jus o Hoel lg o "ul ly d NE d NE J N°6 J N°6 © N= N & N= s 2 N= > 3) N= > NA 7 > Mg > ha > AN = N N N N yo = yj / — A (9 ®
    HN. A N Th. Oxy GA 9 or on 99 Oy GA °° Ose GA 99 à Hol Je o Hol Jw + Hol Je + Hol Je J NE d NRE d y J NE © N= > @ N= s 3) N= > N= N My = Mg = Mg = A > N N N _ oy y= N — / 7 0)» Cn oo N Oo N ° NS Oy A 9 Oy GA 99 Os GA 90 Os GA 99 H H H | Hal 1 © De o a A © À, Hs 0 © (8)
    d. x N N J. a J. a 4. RA AN AR NS 9 NS N N N _ An NN © AR. / J HN OH 9 6
    © © re Og NO N © NO >" ° Cs ou lah °° Oy Hol Ie TN Ae J 8 A / J H 151 Os Na = , > = 3 N= = . ‚ 7 NA ES . N » / NÉ a : ; N { 7 X Ÿ _ Ÿ N _ u NON N 2 Nf Ny NN N SN fo) S N lo 1 H SA, durs q Hs hie J N a 3 DE oh , H 8 J H (sr & Ny à "ee a, N= vi 5 wl 7 ; - J N is) N SS x ] wo) > Es NL Oo N= CJ , N N = N ; A a N J ç J { _ €? < N ÿ X + N NHz Nr N ENO D. olor °> o. a o Oy N © EN TN | SN 0 Ho, Ie , N - oO sh Mis Hog Js y ° N / . N << N 718) y o N < 4, a N ’ ; - „ © ig Oy N= N . =~ Le N = NA a PA Bad + DB N , q / / / { ÿ = ra / he WW M ap oN \ “ Go Og GN 9 63 oy i “a pa of J 0 (SMS, ee Dane VIe / NR TA | diel dy / Se i _ o ©) A , N y €, _ < d À Ve de na = wi : i > NE y=] N } . NA | NÉ | ; 5 N J / _ — A # I ÿ ( ON 7 2 J 7 Ho— 2 \ HO fo) ogo ane TLR ON o Hel de b À due , y z TH Ie ; eZ J vez ‘ a / NTS de N= 5 wel, A g H > = ; i / 5 NA Ng N =? rN ÿ | ~ rN N = ; — Ÿ ÿ Oh ÿ IN N X I Le) x x Le 7 OH Ho (5) oO N a N ] Ogu GA 2, Oy NSP © A fol ds , 4 ol Jw . TN | 5 Mel Le ; N y N D (3), pl AD / N @ d | _ / N RAE d N VO ; N VE « AVE 9 N 5) N= = x . 5 7 NS NS / = "4 ME / 7 NÉ 7 4 4 N — WFC = ÿ — J oo ‘ ® oO nN oh J
    Oy GA O9 Oy GA 99 Oy 2 99 x GA 99 H H H H o ay Aho D À, de 0 À, duo D À, de dr A, FA dr Ne N ve dr N N VE dr Ne N ve SS 5 y= SS NS 4 NS 7 NS NS 7 N À Bi À HO, = HOW 7 Fug ÿ Fa Or © Cr On 0 Pa os, GA 9, Psp GA 90 Oy GA 99 N i Hoo À Hoel À, 0 & Je 5 Hel y Oo Day / OÖ NE de "4, Po de N ve Ae CE VE Ogg n=l " id = 5 5 2 > Nf = Mg NS 7 N N _ — J - {= ÿ / N N Co dp vo] vob oy Gh 9 oy 1 0g oy la) 0g oy 90
    N . a À, ds o Hel H | o "el dr A, A J N eo J 0 whe - J N 2 À, & N= © N= © N= N = 8 5 5 y NZ > Mg 0 > N N N # — ZA ° J — J 9 N > Og AL CO Le) D Os A C4 oy A o ° oy SN o ° 7 o sy y (8) z 3 Hol de / o "uy y} © ; o Hu wl A Os nA N J H 6 o oH vo o H is) N A Si N= Sl NA Ss) N= (AI oN N of N = ® N: = N NA NA NE 7 jf — — — Ww — 7 + 7 A Ÿ N $ N SON oN = oy GA °o oy 6 °e Os (A 99 Oy GA De N ; ° sg 6 Hal dl o Hug J H / N ve / NE / NL ° SA, hg Sg A rs) CM Wd # ve Se nd a qd, N N a N: = Ss s 1 De an a = NA 7 N N N N — — — 5 À A A do — N \ \ of " — 5 < oc + os GA oy oy Ga i oy GA CIN ou lo oy N 1 ° s) (5) à Hl |. o Fe / © Tat te d NU d Ng J of te Og nel MH 4% N= Sl N= Sl N= Ls N = s s N N @ 4 a = NG > À N J N N ÿ — NY Sa 2 \ N N N N N a) = TS \_/ N °
LU505117A 2023-09-15 2023-09-15 A pan-KRAS inhibitor compound LU505117B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
LU505117A LU505117B1 (en) 2023-09-15 2023-09-15 A pan-KRAS inhibitor compound

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
LU505117A LU505117B1 (en) 2023-09-15 2023-09-15 A pan-KRAS inhibitor compound

Publications (1)

Publication Number Publication Date
LU505117B1 true LU505117B1 (en) 2024-03-15

Family

ID=90300600

Family Applications (1)

Application Number Title Priority Date Filing Date
LU505117A LU505117B1 (en) 2023-09-15 2023-09-15 A pan-KRAS inhibitor compound

Country Status (1)

Country Link
LU (1) LU505117B1 (fr)

Similar Documents

Publication Publication Date Title
TWI723511B (zh) 一種高活性sting蛋白激動劑化合物
WO2019158070A1 (fr) Antagoniste du récepteur a2a et/ou a2b
WO2022089454A1 (fr) Composé inhibiteur de la voie wnt à haute activité
CN111548343B (zh) 一种高活性csf1r抑制剂化合物的制备方法
WO2020038387A1 (fr) Agoniste de protéine sting à haute activité
US20230399327A1 (en) High activity hpk1 kinase inhibitor
JP7281834B2 (ja) Ｐｄ－ｌ１拮抗薬化合物
CA3160606A1 (fr) Compose antagoniste de pd-l1
EP4006033A1 (fr) Antagoniste du récepteur de l&#39;adénosine
LU505117B1 (en) A pan-KRAS inhibitor compound
JP7299411B2 (ja) アデノシン受容体拮抗薬
CN111440148B (zh) 一种腺苷受体拮抗剂的制备方法
LU505465B1 (en) A pan-KRAS inhibitor compound
WO2024022365A1 (fr) Composé inhibiteur de la voie wnt
LU505464B1 (en) A pan-KRAS inhibitor compound
WO2022199561A1 (fr) Composé inhibiteur de la kinase hpk1
WO2024104364A1 (fr) Composé inhibiteur de pan-kras
WO2023005894A1 (fr) Composé inhibiteur pour la voie wnt
CN117903169A (zh) 一种pan-KRAS抑制剂化合物
WO2023143546A1 (fr) Composés inhibiteurs de la voie wnt
CN117396482A (zh) 一种Wnt通路抑制剂化合物
WO2022214008A1 (fr) Inhibiteur de la kinase hpk1 hautement actif

Legal Events

Date Code Title Description
FG Patent granted

Effective date: 20240315